PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 14, 2026New England Journal of Medicine0 citations

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

View Full Paper
SNS. NathanPSPeter SmithCDC. Q. Deng

Key Points

  • The aim is to evaluate the efficacy of inhaled treprostinil for improving lung function in patients with idiopathic pulmonary fibrosis (IPF).
  • Conducted a 52-week clinical trial comparing inhaled treprostinil with placebo.
  • Measured forced vital capacity (FVC) as a primary outcome.
  • Documented clinical worsening events.
  • Inhaled treprostinil resulted in a smaller decline in FVC compared to placebo.
  • Fewer clinical worsening events were observed in the treprostinil group than in the placebo group.

Abstract

In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Nathan et al. (2026) studied this question.

synapsesocial.com/papers/69b4fc0eb39f7826a300cb06https://doi.org/10.1056/nejmoa2512911
Ask AI
Helpful
Bookmark
Share
View Full Paper